Seres Therapeutics Inc (MCRB)

$5.01 -0.09 (-1.76%)
Market Cap 50.33M
Revenue (ttm) 790,000.00
Net Income (ttm) 5.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 721.52%
Debt to Equity Ratio 0.00
Volume 39,500
Avg Vol 76,060
Day's Range N/A - N/A
Shares Out 10.05M
Stochastic %K 10%
Beta 0.21
Analysts Strong Sell
Price Target $17.00

Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 945 9626
Address:
101 Cambridgepark Drive, Cambridge, United States
Neptune1870
Neptune1870 Sep. 10 at 8:07 PM
$MCRB red it’s the new green… hope this nightmare will finished soon
0 · Reply
TurdDetect0r
TurdDetect0r Sep. 10 at 6:33 PM
$MCRB Stock getting smoked again. 📉 Amazing shareholder activism on display today, gentlemen. 🤣 Guess none of you pansies sprung for the $5.99 Whitepages subscription. 🤣 Another 300 Stocktwits posts, 46 angry emojis, 17 “management should be ashamed” comments and exactly ZERO actual pressure through legitimate shareholder channels. But don’t worry — I’m sure management is absolutely TERRIFIED of that bearish GIF you posted from your couch. 💀 Keep furiously refreshing the ticker. Maybe Richard Kender will sense the disappointment telepathically. Management gets paid. Shareholders get mad. Nobody does shit. What a system. 😂
0 · Reply
mongoosereflexes
mongoosereflexes Sep. 10 at 4:59 PM
$MCRB anybody done any LinkedIn sleuthing to figure out who the newest two employees are? Would love to know their job titles/roles
1 · Reply
TurdDetect0r
TurdDetect0r Sep. 10 at 11:04 AM
$MCRB Good morning and happy Thursday from another beautiful day in shareholder hell. ☀️📉 At this point I think it’s time for our weekly wellness check on the legendary @BIOhmygod. 💀 The longer this goes on, the more I find myself understanding where this guy’s anger comes from. This is the type of shareholder fury executives and directors bring upon themselves when they screw shareholders over this badly. Years of destruction while management gets paid, awarded equity, and shareholders are left wondering when “shareholder value” actually becomes part of the business model. Shameless, self-serving, greedy bastards. Shareholders deserved better. Another glorious day at Seres Therapeutics. 🏝️🍹
0 · Reply
Tritsortreat2020
Tritsortreat2020 Sep. 10 at 9:53 AM
$MCRB i think theyre just laughing at us seeing how many stock options they can award. these 2 ”new” employees probably dont even exist. its probably the lobby’s goldfish or someones grandmother. these options will probably never even be paid out. #SOLD
0 · Reply
Thepark88
Thepark88 Sep. 9 at 1:59 PM
$MCRB weird that they have actually PR’d this and not just a SEC filing https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-inducement-grants-under-nasdaq-14
5 · Reply
TurdDetect0r
TurdDetect0r Sep. 9 at 12:00 PM
$MCRB Happy Wednesday, shareholders! ☀️ Another beautiful morning at Seres Therapeutics, where the science is promising, the executives are compensated, and shareholder value remains a fascinating theoretical concept. 💀 Management’s weekly checklist: ✅ Show up ✅ Collect paycheck ✅ Award equity ✅ Maintain strategic silence ✅ Allow shareholders to invent 47 different partnership theories ❌ Create shareholder value At this point, $MCRB isn’t an investment. It’s an escape room where management forgot to leave us the fcking clues. 🔐
0 · Reply
Tritsortreat2020
Tritsortreat2020 Sep. 9 at 12:45 AM
$MCRB we were told IREC data would be out in early q2(April) we waited till july for it. here we are in setember down to a ”nearly” 52 week low. jeeze these guys should be strung up. complete disregard for shareholders here. we literally pay their saleries and pay for their stock options and this how they treat us. what a waste of yet another year. GET THIS COMPANY SOLD. $20+ up front with some nice CVRs. GET IT DONE
1 · Reply
I0VA
I0VA Sep. 8 at 4:34 PM
$MCRB if you didn’t see this from yahoo. Pretty positive. https://finance.yahoo.com/healthcare/articles/microbiome-therapeutics-market-report-2026-082700279.html “The global microbiome therapeutics market is projected to increase from USD 0.6 billion in 2026 to USD 4.6 billion by 2035, registering a compound annual growth rate of 25.4% during the forecast period” At this point I hope they announce a buyout soon. I was hoping there would be something substantial after the irec data so I could then buy more iova. Iova was still at $4. The timing would have been perfect. But alas…
0 · Reply
TurdDetect0r
TurdDetect0r Sep. 8 at 11:56 AM
$MCRB Good morning and welcome to another week at the Seres Executive Retreat. 🏝️🍹 Shareholders clocking in Tuesday morning wondering whether this company will ever create shareholder value. Meanwhile, our distinguished leadership team: ☀️ Salaries secured 🍹 Compensation secured 🏖️ Equity awards secured 💼 Titles secured 📉 Shareholder value — missing, presumed dead Another beautiful week to remind everyone that somehow the only people who have consistently made money from $MCRB are the people being paid to run it. 💀 Eric Shaff. Richard Kender. Matthew Henn. Marella Thorell. Kelly Brady. Stephen Berenson. Thomas DesRosier. Chris McChalicher. Ann Kurowski. Dennis Walling. Dennis Ausiello. Willard Dere. Claire Fraser. Kurt Graves. Rob Rosiello. Accountability remains out of office with no expected return date. 🏖️ Until then, enjoy the resort, gentlemen. Shareholders already picked up the tab. 🏝️
1 · Reply
Latest News on MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2026, 6:00 PM EDT - 4 days ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Sep 1, 2026, 7:00 AM EDT - 11 days ago

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Seres Therapeutics files $300M mixed securities shelf

2026-08-16T14:04:51.000Z - 27 days ago

Seres Therapeutics files $300M mixed securities shelf

Seres Therapeutics Registration statement: Registration filing

Aug 13, 2026, 8:00 AM EDT - 4 weeks ago

Seres Therapeutics Registration statement: Registration filing

Seres Therapeutics reports Q2 EPS 47c, consensus ($2.18)

2026-08-05T11:37:49.000Z - 5 weeks ago

Seres Therapeutics reports Q2 EPS 47c, consensus ($2.18)

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

Seres Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Seres Therapeutics Earnings release: Q2 2026

Seres Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Seres Therapeutics Quarterly report: Q2 2026

Seres Therapeutics Transcript: Study result

Jul 8, 2026, 8:30 AM EDT - 2 months ago

Seres Therapeutics Transcript: Study result

Seres Therapeutics Press release: Study result

Jul 8, 2026, 8:30 AM EDT - 2 months ago

Seres Therapeutics Press release: Study result

Seres Therapeutics Slides: Study result

Jul 8, 2026, 8:30 AM EDT - 2 months ago

Seres Therapeutics Slides: Study result

Seres Therapeutics Transcript: AGM 2026

Jul 8, 2026, 8:00 AM EDT - 2 months ago

Seres Therapeutics Transcript: AGM 2026

Seres Therapeutics announces top-line results from SER-155 trial

2026-07-08T11:20:16.000Z - 2 months ago

Seres Therapeutics announces top-line results from SER-155 trial

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

Jul 8, 2026, 7:00 AM EDT - 2 months ago

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

Jun 25, 2026, 7:00 AM EDT - 2 months ago

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

Seres Therapeutics initiated with a Buy at H.C. Wainwright

2026-06-23T10:05:08.000Z - 2 months ago

Seres Therapeutics initiated with a Buy at H.C. Wainwright

Seres Therapeutics announces two transactions

2026-06-05T11:32:52.000Z - 3 months ago

Seres Therapeutics announces two transactions

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

Jun 5, 2026, 7:00 AM EDT - 3 months ago

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

Seres Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 3:30 PM EDT - 3 months ago

Seres Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 7:00 AM EDT - 4 months ago

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 5, 2026, 7:00 AM EDT - 4 months ago

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Seres Therapeutics Earnings release: Q1 2026

May 5, 2026, 7:00 AM EDT - 4 months ago

Seres Therapeutics Earnings release: Q1 2026

Seres Therapeutics Quarterly report: Q1 2026

May 5, 2026, 7:00 AM EDT - 4 months ago

Seres Therapeutics Quarterly report: Q1 2026

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

May 4, 2026, 7:00 AM EDT - 4 months ago

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

Seres Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Seres Therapeutics Proxy statement: Proxy filing

Seres Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Seres Therapeutics Proxy statement: Proxy filing

Seres Therapeutics announces three presentations at 2026 ESCMID congress

2026-04-20T11:36:06.000Z - 4 months ago

Seres Therapeutics announces three presentations at 2026 ESCMID congress

Seres Therapeutics announces three presentations at 2026 ESCMID congress

2026-04-20T11:22:15.000Z - 4 months ago

Seres Therapeutics announces three presentations at 2026 ESCMID congress

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Apr 20, 2026, 7:00 AM EDT - 4 months ago

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Seres Therapeutics to Present at CARB-X Investor Day

Apr 9, 2026, 7:00 AM EDT - 5 months ago

Seres Therapeutics to Present at CARB-X Investor Day

Seres Therapeutics Slides: Company presentation

Mar 13, 2026, 8:00 AM EDT - 6 months ago

Seres Therapeutics Slides: Company presentation

Seres Therapeutics Annual report: Q4 2025

Mar 12, 2026, 3:00 PM EDT - 6 months ago

Seres Therapeutics Annual report: Q4 2025

Seres Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 3:00 PM EDT - 6 months ago

Seres Therapeutics Earnings release: Q4 2025

Seres Therapeutics reports FY25 EPS 64c

2026-03-12T11:15:45.000Z - 6 months ago

Seres Therapeutics reports FY25 EPS 64c

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Seres Therapeutics Transcript: Status update

Mar 3, 2026, 8:30 AM EST - 6 months ago

Seres Therapeutics Transcript: Status update

Seres Therapeutics Earnings release: Status update

Mar 3, 2026, 8:30 AM EST - 6 months ago

Seres Therapeutics Earnings release: Status update

Seres co-CEOs Tom DesRosier, Marella Thorell to step down

2026-03-02T21:50:27.000Z - 6 months ago

Seres co-CEOs Tom DesRosier, Marella Thorell to step down

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Mar 2, 2026, 4:05 PM EST - 6 months ago

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Seres pauses investment in SER-155 program, reports workforce reduction of 30%

2026-02-12T12:20:35.000Z - 7 months ago

Seres pauses investment in SER-155 program, reports workforce reduction of 30%

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Feb 12, 2026, 7:00 AM EST - 7 months ago

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Seres announces publications in Nature Medicine, Journal of Infectious Diseases

2026-01-06T12:22:24.000Z - 8 months ago

Seres announces publications in Nature Medicine, Journal of Infectious Diseases

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

Jan 6, 2026, 7:00 AM EST - 8 months ago

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

Seres Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 10:30 AM EST - 9 months ago

Seres Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 9 months ago

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Seres Therapeutics Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Seres Therapeutics Earnings Call Transcript: Q3 2025

Seres Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Seres Therapeutics Quarterly report: Q3 2025

Seres Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Seres Therapeutics Earnings release: Q3 2025

Seres Therapeutics reports Q3 EPS 94c vs ($6.69) last year

2025-11-05T12:05:47.000Z - 10 months ago

Seres Therapeutics reports Q3 EPS 94c vs ($6.69) last year

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 5, 2025, 7:00 AM EST - 10 months ago

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics Slides: Investor Presentation

Nov 4, 2025, 6:00 PM EST - 10 months ago

Seres Therapeutics Slides: Investor Presentation

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

Oct 30, 2025, 7:00 AM EDT - 10 months ago

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

Seres Therapeutics receives award of up to $3.6M from CARB-X

2025-10-29T11:21:51.000Z - 10 months ago

Seres Therapeutics receives award of up to $3.6M from CARB-X

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Seres Therapeutics to present new post hoc data from SER-155 Phase 1b trial

2025-10-14T11:10:19.000Z - 11 months ago

Seres Therapeutics to present new post hoc data from SER-155 Phase 1b trial

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Oct 14, 2025, 7:00 AM EDT - 11 months ago

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Seres Therapeutics price target raised to $22 from $14 at Canaccord

2025-09-24T10:45:23.000Z - 11 months ago

Seres Therapeutics price target raised to $22 from $14 at Canaccord

Seres Therapeutics announces further constructive feedback from FDA on SER-155

2025-09-23T11:05:25.000Z - 11 months ago

Seres Therapeutics announces further constructive feedback from FDA on SER-155

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Sep 23, 2025, 7:00 AM EDT - 11 months ago

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

More companies adopt co-CEO structure

Sep 22, 2025, 12:10 PM EDT - 11 months ago

More companies adopt co-CEO structure

IREN KKR LEN NFLX ORCL SBET

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Seres Therapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Seres Therapeutics Earnings Call Transcript: Q2 2025

Seres Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Seres Therapeutics Quarterly report: Q2 2025

Seres Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Seres Therapeutics Earnings release: Q2 2025

Seres Therapeutics reports Q2 EPS ($2.27) vs ($4.34) last year

2025-08-06T11:16:41.000Z - 1 year ago

Seres Therapeutics reports Q2 EPS ($2.27) vs ($4.34) last year

Seres Therapeutics expects cash to fund operations into Q1 2026

2025-08-06T11:16:27.000Z - 1 year ago

Seres Therapeutics expects cash to fund operations into Q1 2026

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

SANA

Seres Therapeutics Slides: Investor Presentation

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Slides: Investor Presentation

Seres Therapeutics appoints DesRosier, Thorell as co-CEOs

2025-07-22T11:10:36.000Z - 1 year ago

Seres Therapeutics appoints DesRosier, Thorell as co-CEOs

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Jul 22, 2025, 7:01 AM EDT - 1 year ago

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Seres Therapeutics Announces Leadership Transition

Jul 22, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Leadership Transition

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 27, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

Seres Therapeutics Earnings Call Transcript: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

Seres Therapeutics Earnings Call Transcript: Q1 2025

Seres Therapeutics Quarterly report: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

Seres Therapeutics Quarterly report: Q1 2025

Seres Therapeutics Earnings release: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

Seres Therapeutics Earnings release: Q1 2025

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics Slides: Investor Presentation

May 7, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Slides: Investor Presentation

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Seres Therapeutics Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Seres Therapeutics Earnings Call Transcript: Q4 2024

Seres Therapeutics Annual report: Q4 2024

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Seres Therapeutics Annual report: Q4 2024

Seres Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Seres Therapeutics Earnings release: Q4 2024

Seres Therapeutics Proxy statement: Proxy Filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Mar 3, 2025, 7:00 AM EST - 1 year ago

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Seres Therapeutics Proxy statement: Proxy Filing

Mar 3, 2025, 7:00 AM EST - 1 year ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 10:30 AM EST - 1 year ago

Seres Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Seres Therapeutics Slides: FY 2025

Jan 16, 2025, 10:30 AM EST - 1 year ago

Seres Therapeutics Slides: FY 2025

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Jan 16, 2025, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Jan 9, 2025, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Seres Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 4:30 PM EST - 1 year ago

Seres Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Seres Therapeutics Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Seres Therapeutics Earnings Call Transcript: Q3 2024

Seres Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Seres Therapeutics Quarterly report: Q3 2024

Seres Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Seres Therapeutics Earnings release: Q3 2024

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Seres Therapeutics Registration statement: Registration Filing

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Seres Therapeutics Registration statement: Registration Filing

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Sep 30, 2024, 5:15 PM EDT - 1 year ago

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Sep 27, 2024, 3:26 PM EDT - 1 year ago

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Sep 26, 2024, 4:01 PM EDT - 1 year ago

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Seres Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 3:05 PM EDT - 1 year ago

Seres Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Seres Therapeutics Transcript: Study Result

Sep 12, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Transcript: Study Result

Seres Therapeutics Press release: Study Result

Sep 12, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Press release: Study Result

Seres Therapeutics Slides: Study Result

Sep 12, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Slides: Study Result

Seres Therapeutics Proxy statement: Proxy Filing

Sep 12, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Sep 12, 2024, 7:00 AM EDT - 2 years ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics Proxy statement: Proxy Filing

Aug 26, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Proxy statement: Proxy Filing

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Proxy statement: Proxy Filing

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Earnings Call Transcript: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Earnings Call Transcript: Q2 2024

Seres Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Quarterly report: Q2 2024

Seres Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Earnings release: Q2 2024

Seres Therapeutics Proxy statement: Proxy Filing

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Proxy statement: Proxy Filing

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Proxy statement: Proxy Filing

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Proxy statement: Proxy Filing

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Transcript: Investor Update

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Transcript: Investor Update

Seres Therapeutics Proxy statement: Proxy Filing

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Proxy statement: Proxy Filing

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics Proxy statement: Proxy Filing

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Seres Therapeutics Proxy statement: Proxy Filing

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

Jun 6, 2024, 6:30 AM EDT - 2 years ago

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

Seres Therapeutics Earnings Call Transcript: Q1 2024

May 8, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Earnings Call Transcript: Q1 2024

Seres Therapeutics Quarterly report: Q1 2024

May 8, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Quarterly report: Q1 2024

Seres Therapeutics Earnings release: Q1 2024

May 8, 2024, 8:30 AM EDT - 2 years ago

Seres Therapeutics Earnings release: Q1 2024

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 7:00 AM EDT - 2 years ago

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

May 6, 2024, 9:30 AM EDT - 2 years ago

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Apr 9, 2024, 7:00 AM EDT - 2 years ago

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Neptune1870
Neptune1870 Sep. 10 at 8:07 PM
$MCRB red it’s the new green… hope this nightmare will finished soon
0 · Reply
TurdDetect0r
TurdDetect0r Sep. 10 at 6:33 PM
$MCRB Stock getting smoked again. 📉 Amazing shareholder activism on display today, gentlemen. 🤣 Guess none of you pansies sprung for the $5.99 Whitepages subscription. 🤣 Another 300 Stocktwits posts, 46 angry emojis, 17 “management should be ashamed” comments and exactly ZERO actual pressure through legitimate shareholder channels. But don’t worry — I’m sure management is absolutely TERRIFIED of that bearish GIF you posted from your couch. 💀 Keep furiously refreshing the ticker. Maybe Richard Kender will sense the disappointment telepathically. Management gets paid. Shareholders get mad. Nobody does shit. What a system. 😂
0 · Reply
mongoosereflexes
mongoosereflexes Sep. 10 at 4:59 PM
$MCRB anybody done any LinkedIn sleuthing to figure out who the newest two employees are? Would love to know their job titles/roles
1 · Reply
TurdDetect0r
TurdDetect0r Sep. 10 at 11:04 AM
$MCRB Good morning and happy Thursday from another beautiful day in shareholder hell. ☀️📉 At this point I think it’s time for our weekly wellness check on the legendary @BIOhmygod. 💀 The longer this goes on, the more I find myself understanding where this guy’s anger comes from. This is the type of shareholder fury executives and directors bring upon themselves when they screw shareholders over this badly. Years of destruction while management gets paid, awarded equity, and shareholders are left wondering when “shareholder value” actually becomes part of the business model. Shameless, self-serving, greedy bastards. Shareholders deserved better. Another glorious day at Seres Therapeutics. 🏝️🍹
0 · Reply
Tritsortreat2020
Tritsortreat2020 Sep. 10 at 9:53 AM
$MCRB i think theyre just laughing at us seeing how many stock options they can award. these 2 ”new” employees probably dont even exist. its probably the lobby’s goldfish or someones grandmother. these options will probably never even be paid out. #SOLD
0 · Reply
Thepark88
Thepark88 Sep. 9 at 1:59 PM
$MCRB weird that they have actually PR’d this and not just a SEC filing https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-reports-inducement-grants-under-nasdaq-14
5 · Reply
TurdDetect0r
TurdDetect0r Sep. 9 at 12:00 PM
$MCRB Happy Wednesday, shareholders! ☀️ Another beautiful morning at Seres Therapeutics, where the science is promising, the executives are compensated, and shareholder value remains a fascinating theoretical concept. 💀 Management’s weekly checklist: ✅ Show up ✅ Collect paycheck ✅ Award equity ✅ Maintain strategic silence ✅ Allow shareholders to invent 47 different partnership theories ❌ Create shareholder value At this point, $MCRB isn’t an investment. It’s an escape room where management forgot to leave us the fcking clues. 🔐
0 · Reply
Tritsortreat2020
Tritsortreat2020 Sep. 9 at 12:45 AM
$MCRB we were told IREC data would be out in early q2(April) we waited till july for it. here we are in setember down to a ”nearly” 52 week low. jeeze these guys should be strung up. complete disregard for shareholders here. we literally pay their saleries and pay for their stock options and this how they treat us. what a waste of yet another year. GET THIS COMPANY SOLD. $20+ up front with some nice CVRs. GET IT DONE
1 · Reply
I0VA
I0VA Sep. 8 at 4:34 PM
$MCRB if you didn’t see this from yahoo. Pretty positive. https://finance.yahoo.com/healthcare/articles/microbiome-therapeutics-market-report-2026-082700279.html “The global microbiome therapeutics market is projected to increase from USD 0.6 billion in 2026 to USD 4.6 billion by 2035, registering a compound annual growth rate of 25.4% during the forecast period” At this point I hope they announce a buyout soon. I was hoping there would be something substantial after the irec data so I could then buy more iova. Iova was still at $4. The timing would have been perfect. But alas…
0 · Reply
TurdDetect0r
TurdDetect0r Sep. 8 at 11:56 AM
$MCRB Good morning and welcome to another week at the Seres Executive Retreat. 🏝️🍹 Shareholders clocking in Tuesday morning wondering whether this company will ever create shareholder value. Meanwhile, our distinguished leadership team: ☀️ Salaries secured 🍹 Compensation secured 🏖️ Equity awards secured 💼 Titles secured 📉 Shareholder value — missing, presumed dead Another beautiful week to remind everyone that somehow the only people who have consistently made money from $MCRB are the people being paid to run it. 💀 Eric Shaff. Richard Kender. Matthew Henn. Marella Thorell. Kelly Brady. Stephen Berenson. Thomas DesRosier. Chris McChalicher. Ann Kurowski. Dennis Walling. Dennis Ausiello. Willard Dere. Claire Fraser. Kurt Graves. Rob Rosiello. Accountability remains out of office with no expected return date. 🏖️ Until then, enjoy the resort, gentlemen. Shareholders already picked up the tab. 🏝️
1 · Reply
drdr3
drdr3 Sep. 8 at 4:27 AM
$MCRB Monday 9/14/26 4:05pm Ser-155 FDA news 🙋🏻‍♂️🤞
1 · Reply
TurdDetect0r
TurdDetect0r Sep. 5 at 10:22 PM
$MCRB Requoting @RoelInTheGreen again because apparently this man was documenting the entire shareholder experience in real time. 🤣 High salaries? ✅ Bonuses? ✅ Severance packages? ✅ Shareholders getting absolutely obliterated? ✅ Executives reaching into their own pockets to load up on this “incredible opportunity”? 🦗🦗🦗 Funny how the people closest to the company always seem perfectly comfortable letting the shareholder's money demonstrate their confidence. Roel wasn’t bearish. Bro was conducting an audit. 💀
0 · Reply
Tritsortreat2020
Tritsortreat2020 Sep. 5 at 9:35 AM
$MCRB 🖕this is for turd,roelle, and anyone else who is a POS on this thread 😘
2 · Reply
RoelInTheGreen
RoelInTheGreen Sep. 5 at 5:01 AM
$MCRB I NEVER saw any employee buying a single share of this company. I DID saw high salaries, high bonuses, high severance packages. This should be illegal. How many people lost money because of them? Thousands probably…
1 · Reply
TurdDetect0r
TurdDetect0r Sep. 4 at 10:18 PM
$MCRB Imagine bulls sitting here hoping and praying for $6. That’s $0.30 pre-split. What a shame. The longer this goes on, the more I find myself understanding where this guy’s anger comes from. 💀 This is the type of shareholder fury executives and directors bring upon themselves when they screw shareholders over this badly. Shameless, self-serving, greedy bastards. Shareholders deserved better.
0 · Reply
TurdDetect0r
TurdDetect0r Sep. 4 at 10:08 PM
$MCRB
0 · Reply
Tritsortreat2020
Tritsortreat2020 Sep. 4 at 2:11 PM
$MCRB $7-$10-$12.50-$16.00
1 · Reply
TurdDetect0r
TurdDetect0r Sep. 4 at 1:57 PM
$MCRB
0 · Reply
mongoosereflexes
mongoosereflexes Sep. 4 at 10:58 AM
$MCRB wen Honda civic? (Base model)
1 · Reply
Tritsortreat2020
Tritsortreat2020 Sep. 3 at 7:35 PM
$MCRB weve been battered and beaten for 3 years. surely this will go on a 200+% run from here
1 · Reply
steven1x
steven1x Sep. 3 at 3:48 PM
$MCRB updates?
0 · Reply
steven1x
steven1x Sep. 3 at 3:48 PM
$MCRB https://www.globenewswire.com/news-release/2026/09/01/3353940/0/en/seres-therapeutics-to-participate-in-h-c-wainwright-28th-annual-global-investment-conference.html
0 · Reply